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The ratio of monocytes and lymphocytes (ML ratio) in peripheral blood is associated with tuberculosis and ma-
laria disease risk and cancer and cardiovascular disease outcomes. We studied anti-mycobacterial function and
the transcriptome of monocytes in relation to the ML ratio.
Mycobacterial growth inhibition assays of whole or sorted blood were performed and mycobacteria were enu-
merated by liquid culture. Transcriptomes of unstimulated CD14+monocytes isolated bymagnetic bead sorting
were characterised bymicroarray. Transcript expressionwas tested for associationwithML ratio calculated from
leucocyte differential counts by linear regression.
The ML ratio was associated with mycobacterial growth in vitro (β= 2.23, SE 0.91, p = 0.02). Using sorted
monocytes and lymphocytes, in vivo ML ratio (% variance explained R2 = 11%, p = 0.02) dominated over in
vitro ratios (R2 = 5%, p = 0.10) in explaining mycobacterial growth. Expression of 906 genes was associated
with the ML ratio and 53 with monocyte count alone. ML-ratio associated genes were enriched for type-I and -II
interferon signalling (p = 1.2 × 10−8), and for genes under transcriptional control of IRF1, IRF2, RUNX1,
RELA and ESRRB. The ML-ratio-associated gene set was enriched in TB disease (3.11-fold, 95% CI: 2.28–4.19,
p = 5.7 × 10−12) and other inﬂammatory diseases including atopy, HIV, IBD and SLE.
TheML ratio is associatedwith distinct transcriptional and anti-mycobacterial proﬁles ofmonocytes thatmay ex-
plain the disease associations of the ML ratio.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The diagnostic utility and prognostic value of leucocyte differential
counts were appreciated contemporaneously with the development of
microscopy methods to distinguish leucocyte subsets in 1880 (Ehrlich,
1880). A growing body of evidence suggests that the ratio of leucocyte
subsets may be of similar, or greater, prognostic import than absolute
counts. Although a full blood count is amongst themost frequently per-
formed assays in clinical practice, the monocyte:lymphocyte (ML ratio)
is not a widely-used parameter or biomarker in clinical care.
Florence Sabin and colleagues reported in the 1920s that the ML
ratio was associated with progress and outcomes of mycobacterial in-
fections in rabbits (Cunningham et al., 1925; Sabin et al., 1926; Doan
and Sabin, 1930). Rediscovering this experimental work, we recently
performed a series of prospective cohort studies of adults, infants and
pregnant women in sub-Saharan Africa (Naranbhai et al., 2014a,
2014b, 2014c). In each studywe observed that elevatedML ratiowas as-
sociated with the risk of subsequent tuberculosis disease. We, and
others, made similar observations for malaria (Warimwe et al., 2013a)
and extended these to demonstrate that the ML ratio stratiﬁes efﬁcacy
of the candidate anti-malaria RTS,S vaccine (Warimwe et al., 2013b).
Other investigators have shown that an elevated ratio is associated
with poor outcomes of nasopharyngeal carcinoma (Lin et al., 2014a; Li
et al., 2013), diffuse large B-cell (Li et al., 2012, 2014a, 2014b;
Rambaldi et al., 2013; Koh et al., 2014; Markovic et al., 2014; Porrata
et al., 2014a, 2014b; Watanabe et al., 2014; Wei et al., 2014; Yan-Li
et al., 2014) and Hodgkin's (Koh et al., 2012; Porrata et al., 2012,
2013a, 2013b; Romano et al., 2012) lymphomas, multiple myeloma
(Shin et al., 2013), clear-cell renal carcinoma (Hutterer et al., 2014),
non-small cell lung cancer (Lin et al., 2014b), soft tissue sarcoma
(Szkandera et al., 2014) and colon cancer (Stotz et al., 2014).
The neutrophil:lymphocyte (NL) ratio, another measure of the
myeloid:lymphoid cell proportion, has also been reported to be associ-
ated with cardiovascular and cancer outcomes (Guthrie et al., 2013;
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Templeton et al., 2014; X.Wang et al., 2014). Since theML and NL ratios
are strongly correlated it is unclear whether one is a better predictor
than the other. The pathophysiologic basis for association of
myeloid:lymphoid cell ratios across diseases remains unclear.
Here we studied pathophysiologic mechanisms for the association
between the ML ratio and mycobacterial disease susceptibility. We
studied anti-mycobacterial and transcriptomic proﬁles of monocytes
from healthy adult donors and found that qualitative differences in
monocyte function partially explain theML ratio associationwithmyco-
bacterial growth ex vivo. Whole-transcriptome analysis of monocytes
suggests that the ML ratio (but not the monocyte count) is a marker
of monocyte function and that an elevated ratio is associated with an
enrichment of interferon-associated transcripts in monocytes. We
show that the transcript signature of elevated ML ratio overlaps with
mycobacterial and several other disease transcriptomic signatures
such as atopy and inﬂammatory bowel disease. Taken together our
data suggest that the ML ratio may be associated with disease by acting
as a marker of monocyte function.
2. Materials and Methods
2.1. Study Participants
We recruited 144 healthy adult Caucasian volunteers in Oxford,
United Kingdom (Fairfax et al., 2014). A healthcare professional (nurse
or physician) conducted a verbal review of clinical history to determine
eligibility based on the absence of any major chronic illness, current
medication administration or symptoms of infection. The median age
of the 144 recruits was 32 years (IQR 24–41) and 76 (53%) were female.
Formycobacterial growth inhibition assays,we included individualswho
had received BCG, were negative by interferon-gamma release assay
(IGRA) and had no history of tuberculosiswhereas for transcriptomic ex-
periments, donors had no history of tuberculosis but their BCG history
and IGRA status was not veriﬁed.
2.2. Ethics Statement
This study was approved by the Oxfordshire Research Ethics Com-
mittee (COREC reference 06/Q1605/55 & 10/H0505/3) and each indi-
vidual gave written informed consent to participation.
2.3. Full Blood Counts
Leucocyte differential countswere performed at the Oxford Radcliffe
Hospitals Pathology Laboratory, an accredited clinical laboratory, using
standard procedures on a Sysmex automated haematology analyser.
The ML ratio was calculated as the quotient of the absolute monocyte
and lymphocyte counts.
2.4. Isolation of Monocytes
Whole blood was collected into sodium-heparin containing blood
collection tubes (Becton Dickinson) and processed with 4–6 h after col-
lection. The methods used in monocyte isolation have been previously
described (Fairfax et al., 2014) but brieﬂy, we isolated peripheral blood
mononuclear cells by density gradient centrifugation of blood-diluted
with Hanks Buffered Saline solution (HBSS, Life Technologies, UK) lay-
ered on Lymphoprep (Axis-Shield, Norway), and sorted CD14+mono-
cytes using magnetic-activated cell sorting (MACS, Miltenyi Biotech).
The CD14- fraction was used in recreating ML ratios after counting cells
by microscopy.
2.5. Mycobacterial Growth Inhibition Assays
Whole blood or mixed leucocyte growth inhibition assays were per-
formed using the BACTEC mycobacteria growth indicator tube (MGIT)
system (Becton Dickinson) as previously described (Wallis et al.,
2001), with the exception that whole blood was incubated with BCG
(Pasteur) for 96 h instead of 72 h and mixed leucocytes (monocytes +
non-monocytes = total 1 × 106 live cells) incubated with BCG Pasteur
for 72 h. Growth inhibitionwas determined by calculating time to positiv-
ity (TTP) in the sample and TTP in the control (cell free culture) and
converting to colony-forming units using a standard curve.
2.6. Gene Expression
RNA from 5 × 105 sorted monocytes was extracted using the Qiagen
RNAeasy kit (Qiagen, UK). RNA was quantiﬁed and integrity assessed
using a Bioanalyser RNA 6000 Nano kit (Agilent, UK). Gene expression
was quantiﬁed using the Illumina HumanHT-12 v4 BeadChip gene ex-
pression array platform with 47,231 probes according to the
manufacturer's instructions. Samples were randomly placed across ex-
pression chips and run in a single batch. Gene expression data were nor-
malized using random-spline normalization, transformed by variance-
stabilising transformation and sample outliers were iteratively removed
and normalization repeated. We excluded 8 individuals as sample
outliers.
Probe sequences mapping to more than one genomic location or re-
gions with underlying polymorphisms frequent in N1% of the popula-
tion were excluded from analysis (n = 18,220 probes). Only probes
that were expressed and detected (GenomeStudio probe detection
p b 0.01) in monocytes were included in the analysis.
2.7. Transcription Factor Binding Site Analysis
We used oPOSSUM (Kwon et al., 2012) v3.0 to perform single-site
analysis with the JASPAR core reference and the following search pa-
rameters: conservation cutoff = 0.4, matrix score threshold = 85%
and upstream and downstream sequence lengths 10,000 bp. Of 906
genes submitted for analysis 821 matched genes in the database.
2.8. Statistical Methods
Analyses were conducted in R, using the packages: limma, lumi and
‘vsn’,. For data presentation the ‘gridExtra’, ‘ggbio’ and ‘ggplot2’
packages were used. Linear regression adjusting for age and sex was
performed using the lm function in R. Enrichment analyses were per-
formed using the ﬁsher.test function in R comparing the observed vs.
expected overlap in gene lists.
Ingenuity Pathway Analysis where used, was performed using a
background set of all human genes on the Ilumina array. A listing of ex-
ternal ﬁles and their sources is given in Supplementary Table 14. FDR
where shown denotes the false discovery rate calculated using the
Benjamini Hochberg procedure using the p.adjust function.
2.9. Accession Numbers
Gene expression data is available through ArrayExpress (E-MTAB-
2232). The accession numbers of studies accessed through the
ExpressionAtlas are shown in Supplementary Table 4.
3. Results
3.1. Qualitative Differences inMonocytes Dependent onML Ratio Dominate
Over Quantitative Differences in Explaining the ML Ratio Association With
Mycobacterial Growth
Recent epidemiological studies (Naranbhai et al., 2014b) suggest
that elevated peripheral bloodML ratio is associated with risk of TB dis-
ease in adults, infants and pregnant women. To evaluate whether this
ﬁnding is replicated ex vivo, we cultured whole blood from healthy
adult donors with BCG (Pasteur) in a mycobacterial growth inhibition
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assay (Wallis et al., 2001). The in vivoML ratio calculated fromwhite cell
differential counts in donorswas signiﬁcantly associatedwith enhanced
mycobacterial growth ex vivo (β= 2.23, SE = 0.91, p = 0.02, Fig. 1A).
To distinguish between a quantitative effect of increasing numbers
of monocytes providing more target cells to support mycobacterial
growth, versus a qualitative effect of monocytes from individuals with
higher ML ratio being relatively inferior at inhibiting mycobacterial
growth, monocytes and lymphocytes were sorted from blood of 13
healthy adults, mixed at ratios in vitro that approximate the 25th, 50th
and 75th centiles of ML ratios for adult populations and cultured with
BCG (Pasteur). Higher in vitroML ratio tended to be associated with el-
evatedmycobacterial growth, however individualswith higherML ratio
in vivo supported greatermycobacterial growth regardless of the in vitro
ML ratio that was created by mixing sorted cells (Fig. 1B) suggesting
that qualitative differences play a role beyond quantitative differences.
In a multivariate linear regression model, the in vivo ML ratio
(β= 3.22, SE = 1.30, p = 0.02) but not the in vitroML ratio (β= 1.12,
SE = 0.67, p = 0.10) was signiﬁcantly associated with mycobacterial
growth (Fig. 1C) suggesting that qualitative effects dominate over quan-
titative effects in explaining monocyte capacity to control mycobacterial
growth.
3.2. Transcriptional Proﬁles of Monocytes Dependent on the ML Ratio
To understand the qualitative differences in monocytes from indi-
viduals with varying ML ratio, we analysed data for CD14+monocytes
from 136 healthy European volunteers from Oxfordshire UK (68 male,
68 female, median age = 31.5 years, IQR 24–41) a subset of a cohort
for whom we have generated transcriptome-wide proﬁling using the
Illumina HT12v4 gene expression array (Fairfax et al., 2014). Donors
were representative of a young healthy adult population in a region
with low endemicity of mycobacterial disease. The median monocyte
count was 0.4 (IQR 0.3–0.48) × 109/L and median lymphocyte count
1.81 (IQR 1.54–2.12) × 109/L. After quality control procedures
(Methods), we evaluated 10,104 genes (13,393 probes) that were ro-
bustly detected by high ﬁdelity probes and were expressed in N5%
donors.
We tested for association between the level of each transcript and
either the monocyte count alone, lymphocyte count alone or the ML
ratio (in each case adjusting for age and sex). The expression level of
53 genes (55 probes) was signiﬁcantly associated (false discovery rate
(FDR) b 0.05) with monocyte counts; 0 genes with lymphocyte count
and 906 genes (991 probes) with ML ratio (Supplementary Table 1).
For 51 of 53 genes (96%) whose expression was associated with mono-
cyte counts, expression was also associated with the ML ratio; in these
cases monocyte counts and ML ratio explained a similar proportion of
overall gene expression variance (median 12.3% vs 13.4%, p = 0.6).
Taken together these data suggest that the ML ratio reﬂects a larger de-
gree of the monocyte transcriptome than monocyte counts alone, and
conﬁrms, as per the null expectation, that the monocyte transcriptome
is independent of lymphocyte count.
Of 906 genes (991 probes) associated with theML ratio (Fig. 2A), an
elevated ML ratio was associated with reduced expression of 282 genes
(296probes) such as ETS1 and AFF3 (Fig. 2B–C), and elevated expression
of 624 genes (695 probes) such as HP (haptoglobin) and RUNX1 (Fig.
2D–E).
3.3. ML Ratio Associated Gene Transcripts are Enriched for Interferon
Signalling
Interferon signalling (Fig. 3) was the most signiﬁcantly enriched
(p = 1.2 × 10−8) canonical pathway (p b 0.05) (Supplementary
Table 2). The ﬁve most signiﬁcant upstream regulators were IFNL1
(p = 5.1 × 10–23), IFNA2 (p = 2.4 × 10–17), TGM2 (p = 9.2 × 10–
16), MAPK1 (p = 5.1 × 10–15) and IFNG (p = 1.1 × 10–13). Genes
downstream of IFNL1, IFNA2, TGM2 and IFNG were enriched and mark-
edly activated whilst genes downstream ofMAPK1 were enriched and
markedly inhibited. Several other regulators involved in interferon sig-
nalling are similarly enriched (Supplementary Table 3) including TLR3,
IFNA, TNF, IFN1B, IFNAR2 and STAT1.
3.4. Transcription Factor Binding Analysis
To further investigate the direction of association between ML ratio
and monocyte transcriptomes, we considered whether the set of differ-
entially expressed genes could be more parsimoniously explained by
changes in expression of transcription factors. Of the 906ML-ratio asso-
ciated genes, 79 are human transcription factors, similar to the expected
Fig. 1. TheML ratio is associatedwithmycobacterial growth ex vivo, but the in vivoML ratio of the donor dominates in explainingmycobacterial growth in a growth inhibition assay. (A) In
a mycobacterial growth assay in which whole blood from healthy human adult donors (n= 29) was co-cultured with BCG Pasteur for 96 h andmycobacterial growth assessed by liquid
culture, theML ratio is associatedwithmycobacterial growth. Eachdonor is indicated by a dot that is coloured according to the in vivoML ratio. A regression line and 95% CI is shown in red
and grey respectively. (B) CD14+monocytes and lymphocytes sorted fromhealthy human adult donors (n=13)were combined in vitro at ratios that approximate the 25th (0.04), 50th
(0.19) and 75th (0.30) centiles of the background population and culturedwith BCG Pasteur for 72 h andmycobacterial growth assessed by liquid culture. Lymphocytes alonewere added
to the control tube (denoted asML ratio=0). Each donor is indicated by a dot that is coloured according to the in vivoML ratio. Boxes denote the 25th, 50th and 75th centiles andwhiskers
extend tomedian±1.5 ∗ IQR. (C) In amultivariate linear regressionmodel of data frompart B, the in vivoML ratio signiﬁcantly explains 11% of the variance inmycobacterial growthwhilst
the in vitro ratio explains 5% of variance, albeit not statistically signiﬁcant.
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proportion (OR 0.85 95% CI 0.67–1.07) (Ravasi et al., 2010). Amongst
the 38 transcription factors that were positively associated with ML
ratio are E2F4, STAT6, SP100, IRF1 and IRF7. Amongst the 41 transcription
factors that were negatively associated withML ratio are ETS1, NOTCH2,
KLF12 and JUND (Supplementary Table 1).
To characterise this further, we proceeded to test whether ML ratio-
associated genes were enriched for speciﬁc transcription factor binding
consensus binding sites (TFBS) using oPOSSUM (Kwon et al., 2012).
TFBS for IRF1/IRF2, RUNX1, RELA and ESRRB were enriched for in the
genes associated with theML ratio (Fig. 4). These data suggest that con-
sequent upon upstream events such as interferon stimulation, tran-
scription factors such as IRF1 may be involved in observed variation in
monocyte transcriptomes.
3.5. Representation of ML Associated Transcripts in Human Diseases
In view of the apparent broad association of the ML ratio with
malignant and non-malignant disease outcomes, we explored
whether the set of ML associated genes in monocytes was enriched
for amongst genes differentially expressed in blood in any of
151 human disease conditions curated in the Expression Atlas
(Petryszak et al., 2014). For 19 disorders, there is signiﬁcant enrich-
ment for the ML transcript signature (Supplementary Table 4). These
include atopy (FDR= 3.33 × 10−18), HIV (FDR 1.44 × 10−10), the in-
ﬂammatory bowel diseases (FDR = 6.99 × 10−8) ulcerative colitis
and Crohn's disease, meningeal (FDR = 4.97 × 10−4), pulmonary
(FDR = 1.66 × 10−3) and latent (FDR = 1.08 × 10−3) tuberculosis,
systemic lupus erythematosus (FDR = 4.36 × 10−3) and type 1 dia-
betes mellitus (FDR = 5.1 × 10−3).
3.6. ML Associated Transcripts are Enriched for Genes that are Differentially
Expressed During TB Disease and for TB-Disease Susceptibility Associated
Genes
On the basis of the epidemiologic associations, the in vitro data
presented here and apparent enrichment for ML associated tran-
scripts in a TB dataset curated in the Expression Atlas, we tested
whether the ML associated gene set was similarly enriched in eight
studies of tuberculosis not contained within the Expression Atlas
that were recently collated and meta-analysed (Joosten et al.,
2013). We observed a 3.50-fold (95% CI 2.64–4.61, p =
1.95 × 10−16) enrichment for TB disease-associated genes amongst
ML associated genes, conﬁrming that the transcriptomic changes
during TB disease partially consist of ML-associated transcripts.
These data are consistent with the observed elevation of the ML
ratio during active TB disease (J. Wang et al., 2014).
In the absence of transcriptomic signatures that associate with TB
susceptibility we examined genes that have been implicated in TB sus-
ceptibility by candidate gene studies (Supplementary Table 5). Of 95
genes for which variants have been reportedly associated with TB, 56
are expressed and detected in monocytes and were tested for associa-
tion with ML ratio. Eleven of 906 (1.2%) ML associated genes have
been implicated in TB through candidate gene studies, a 2.5-fold (95%
CI 1.16–4.93, p = 0.02) enrichment over background (45/9198,
Fig. 2.Monocyte transcriptomes are associatedwith theML ratio of the human donor. (A) TheML ratio 139 individualswas associatedwith expression of 906 genes in CD14+monocytes
as shown in this heat map where donors are arranged according to ML ratio (along top), and direction of ML ratio-gene expression association (along right side). The key (top right) de-
notes colouring of individuals according to theML ratio (top) and genes according to expression level (B-C) ETS1, encoding for a transcription factor involved in cytokine transcription, and
AFF3, encoding for a transcription factor involved in lymphoid development, are examples of genes whose expression is negatively associated with ML ratio. In contrast (D-E) HP, which
encodes for haptoglobin and RUNX1, encoding a transcription factor, are positively associated with ML ratio. In panels b–e, the regression line and 95% CI are shown in red and grey
respectively.
Fig. 3.Monocyte genes associated with theML ratio are enriched for genes in the interferon signalling pathway. The intensity of association with ML ratio is denoted in shades of red (in-
creased) or green (decreased) proportionate to the level of expression and symbols denote the type of molecule. The text beneath each symbol denotes the effect size (beta) estimate
between ML ratio and gene expression.
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0.049%). These were CCL5, DEFB1, FCGR2A, HP, IRF1,MCL1, TAPBP, TIRAP,
TLR4, TLR8 and SP110. This suggests that theML ratio associationwith TB
may, at least partly, overlap with genes in which genetic variation af-
fects susceptibility.
4. Discussion
The relative frequency of myeloid and lymphoid cells is increasingly
recognised as a variable distinct from its constituents, but the pathophys-
iologic basis of association remains unclear. Our observation ofmonocyte
functional and transcriptional differences dependent on the ML ratio
(but on neither constituent alone) suggests that qualitative differences
in monocytes are better reﬂected by the ML ratio than by monocyte
counts alone, potentially explaining epidemiologic associations of the
ratio. The signiﬁcant enrichment of interferon signalling we found sup-
ports a common role for type I and II interferons in altering the ML
ratio and monocyte function sufﬁciently to explain altered disease
course, consistent with the central role of interferons in mycobacterial
and inﬂammatory diseases (Mayer-Barber et al., 2014). Additionally, al-
teration inmonocyte functionmay alter crosstalk with lymphocytes and
adaptive immune responses (Zhong and Yazdanbakhsh, 2013), hence
changes in monocyte function alone may have repercussions on other
aspects of the immune response that are detrimental. Finally,we demon-
strate that the transcripts that are associated with the ML ratio are
enriched in tuberculosis using external datasets and report evidence
for a pathophysiologic role of ML-ratio associated genes in several
other disease conditions.
Frequencies of leucocyte subsets in peripheral blood are a result of
lineage commitment events during haematopoiesis, sequestration or
egress into tissue and survival. Changes in cell fate are well described
for lymphocytes, for example both bacterial and viral infection
(Hotchkiss et al., 2013; Merekoulias et al., 2010; McClain et al., 2013)
depress peripheral and splenic lymphocyte counts, and cause wide-
spread lymphocyte apoptosis (Hotchkiss et al., 2013). Compared with
lymphocytes, much less is known about reactive changes in monocyte
number or function. Clonal analysis in mice demonstrates that
haematopoietic stem cells have distinct lineage biases and can be classi-
ﬁed as myeloid-biased, balanced or lymphoid-biased depending on the
relative proportions of myeloid and lymphoid progeny they give rise to
(Muller-Sieburg et al., 2012). In mice, myeloid-biased HSC differentia-
tion has been shown to be under the control of IFN-γ (Matatall et al.,
2014). In humans, myeloid-biased HSC accumulate with age and ex-
plain the relative increase in myeloid cells in blood with age (Pang
et al., 2011). Therefore changes in ML ratio in blood are likely a marker
of changes in the frequency of lineage-biased HSC. Intriguingly, myco-
bacterial infection has been shown to alter haematopoiesis through ele-
vated IFN-γ levels (Baldridge et al., 2010). In murine models, ontogeny
affects the functional capacity of the progeny of myeloid-biased HSC
(Gekas and Graf, 2013; Muller-Sieburg et al., 2004). This ﬁnding is reca-
pitulated in humans in whom granulocyte-monocyte progenitors give
rise to distinctmyeloid subsets, are increased in the circulation, and por-
tend impaired outcomes in a range of solid organ malignancies (Wu
et al., 2014). The causal pathway is difﬁcult to unambiguously ascertain
but positioning our data in this context suggest a model in which in-
ﬂammatory signals - particularly interferons - affect the ML ratio
through lineage-bias during haematopoiesis and this has a lasting effect
on the transcriptional and functional proﬁle of the monocyte progeny.
Our study is limited in ability to exhaustively examine all potential
mechanisms in operation. We studied only CD14+ monocytes and it
is possible that changes in othermonocyte subsetsmay occur. Our eval-
uation ofML ratio transcripts in other diseases is limited to bioinformat-
ic overlap with data curated in the Expression Atlas. Further studieswill
be required to conﬁrm a role, if any, of theML ratio in these disorders as
it is plausible that the overlap is driven by common involvement of in-
terferon pathways in these disorders. Finally, our study suggests that
the ML ratio and monocyte function may be a consequence of inﬂam-
matory processes acting, in part, through interferons. Identifying up-
stream drivers and feedback loops of these inﬂammatory processes
requires further study, but may yield understanding of how to clinically
address the pathophysiological basis of the disease association.
Collectively our data suggest that elevation in theML ratio is associat-
ed with transcriptional changes in monocytes that may account for im-
paired anti-mycobacterial proﬁles of monocytes, potentially explaining
some pathophysiologic disease associations of the ML ratio.
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